

International Congress on **VIRAL HEPATITIS CONFERENCE**

April 18-19, 2022 | Webinar

BIOMARKER ANALYSIS AS A DIAGNOSTIC APPROACH IN HEPATOCELLULAR CARCINOMA**Lekshmi R Nath***Amrita School Of Pharmacy, India*

Hepatocellular carcinoma (HCC) ranks fourth among the leading causes of cancer-related mortality. The development of specific noninvasive or diagnostic markers from blood, urine and feces may represent a valuable tool for detecting HCC at an early stage. Biomarkers help in the prediction of prognosis or recurrence, selection of appropriate treatment modality, and signify novel potential targets for therapeutic interventions. We summarize the most relevant existing data about various biomarkers involved in the progression of HCC.

Biography

Dr Lekshmi R Nath is currently working as an Assistant professor in the Department of Pharmacognosy at Amrita school of Pharmacy, Kochi, India. She obtained her M.Pharm in Pharmacognosy from Rajiv Gandhi University of Health Sciences, India in 2008. After this, she joined Rajiv Gandhi Centre for Biotechnology, Kerala, India, and received her Doctorate in Biotechnology in 2016. Her PhD findings on hepatocellular carcinoma recently received four international patents, US, Canadian, Japan and South Korean Patent (WO 2017208254 A1, "Uttroside B And Derivatives Thereof As Therapeutics For Hepatocellular Carcinoma". The FDA has recently granted an orphan drug designation to the small molecule chemotherapeutic uttroside-B against hepatocellular carcinoma. Q BioMed, a biopharmaceutical company has already started a clinical trial for uttroside B against Hepatocellular carcinoma. She has more than 13 years of research experience with over 30 publications. She has published several publications in many renowned International Journals including Scientific Reports, Plose ONE, RSC Advance, Frontiers in Microbiology etc. Her key research interest includes phytomedicine and Hepatocellular carcinoma, liposomal drug delivery etc